Decreased frequency, but normal functional integrity of mesenchymal stromal cells derived from untreated and Imatinib-treated chronic myeloid leukemia patients.

被引：9
作者：
Estrada-Gonzalez, P. K. [1 ,6 ]
Gomez-Ceja, L. [1 ,6 ]
Montesinos, J. J. [2 ]
Mayani, H. [3 ]
Chavez-Gonzalez, A. [4 ]
Meillon, L. [5 ]
Delgado, N. [5 ]
Sanchez-Nava, E. [5 ]
Flores-Figueroa, E. [1 ]
机构：
[1] Oncol Hosp, Niche & Microenvironm Lab, Oncol Res Unit, Mexico City, DF, Mexico
[2] Oncol Hosp, Mesenchymal Stem Cells Lab, Oncol Res Unit, Mexico City, DF, Mexico
[3] Oncol Hosp, Hematopoiet Stem Cells Lab, Oncol Res Unit, Mexico City, DF, Mexico
[4] Oncol Hosp, Leukemic Stem Cells Lab, Oncol Res Unit, Mexico City, DF, Mexico
[5] IMSS, Bernardo Sepulveda Hosp, Natl Med Ctr, Hematol Serv, Mexico City, DF, Mexico
[6] Univ Nacl Autonoma Mexico, Mexico City 04510, DF, Mexico
来源：
LEUKEMIA RESEARCH | 2014年 / 38卷 / 05期
关键词：
Imatinib; Mesenchymal stromal cells; Bone remodeling; Chronic myeloid leukemia; Fibrosisa; CHRONIC MYELOGENOUS LEUKEMIA; BONE-MARROW; STEM-CELLS; IN-VITRO; MYELODYSPLASTIC SYNDROMES; CYTOGENETIC RESPONSES; CHRONIC-PHASE; GROWTH-FACTOR; MESYLATE; DIFFERENTIATION;
D O I：
10.1016/j.leukres.2014.02.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In vitro, Imatinib inhibits the proliferation and stimulates the osteogenic and adipogenic differentiation of mesenchymal stromal cells (MSC). However, it is unknown whether Imatinib affects the biology of MSC in vivo. We asked whether MSC from long-term Imatinib-treated CML patients were affected by the in vivo treatment. MSC from untreated and Imatinib-treated patients displayed normal functional properties (i.e. proliferation, immunophenotype, differentiation and hematopoietic supportive capacity) - but a decreased frequency. In vitro, Imatinib lost its effect when discontinued; which suggest that it has a reversible effect on MSC. Therefore it might lose its effect on MSC after discontinuation in vivo. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码：594 / 600
页数：7
相关论文
共 33 条
  • [1] Altered bone and mineral metabolism in patients receiving imatinib mesylate
    Berman, E
    Nicolaides, M
    Maki, RG
    Fleisher, M
    Chanel, S
    Scheu, K
    Wilson, BA
    Heller, G
    Sauter, NP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (19) : 2006 - 2013
  • [2] Buchdunger E, 1996, CANCER RES, V56, P100
  • [3] Mesenchymal stem cells from patients with chronic myeloid leukemia do not express BCR-ABL and have absence of chimerism after allogeneic bone marrow transplant
    Carrara, R. C. V.
    Orellana, M. D.
    Fontes, A. M.
    Palma, P. V. B.
    Kashima, S.
    Mendes, M. R.
    Coutinho, M. A.
    Voltarelli, J. C.
    Covas, D. T.
    [J]. BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2007, 40 (01) : 57 - 67
  • [4] Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved hematological remission after different therapeutic procedures
    Chávez-González, A
    Ayala-Sánchez, M
    Sánchez-Valle, E
    Ruiz-Sánchez, E
    Arana-Trejo, RM
    Vela-Ojeda, J
    Mayani, H
    [J]. LEUKEMIA RESEARCH, 2006, 30 (03) : 286 - 295
  • [5] Imatinib as a potential antiresorptive therapy for bone disease
    Dewar, Andrea L.
    Farrugia, Amanda N.
    Condina, Mark R.
    To, L. Bik
    Hughes, Timothy P.
    Vernon-Roberts, Barrie
    Zannettino, Andrew C. W.
    [J]. BLOOD, 2006, 107 (11) : 4334 - 4337
  • [6] Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement
    Dominici, M.
    Le Blanc, K.
    Mueller, I.
    Slaper-Cortenbach, I.
    Marini, F. C.
    Krause, D. S.
    Deans, R. J.
    Keating, A.
    Prockop, D. J.
    Horwitz, E. M.
    [J]. CYTOTHERAPY, 2006, 8 (04) : 315 - 317
  • [7] Inhibition of platelet-derived growth factor receptorβ by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro
    Fierro, F.
    Illmer, T.
    Jing, D.
    Schleyer, E.
    Ehninger, G.
    Boxberger, S.
    Bornhaeuser, M.
    [J]. CELL PROLIFERATION, 2007, 40 (03) : 355 - 366
  • [8] Long-term imatinib therapy promotes bone formation in CML patients
    Fitter, Stephen
    Dewar, Andrea L.
    Kostakis, Panagiota
    To, L. Bik
    Hughes, Timothy P.
    Roberts, Marion M.
    Lynch, Kevin
    Vernon-Roberts, Barrie
    Zannettino, Andrew C. W.
    [J]. BLOOD, 2008, 111 (05) : 2538 - 2547
  • [9] Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion
    Fitter, Stephen
    Vandyke, Kate
    Gronthos, Stan
    Zannettino, Andrew C. W.
    [J]. JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2012, 48 (03) : 229 - 240
  • [10] Mesenchymal stem cells in myelodysplastic syndromes:: phenotypic and cytogenetic characterization
    Flores-Figueroa, E
    Arana-Trejo, RM
    Gutiérrez-Espíndola, G
    Pérez-Cabrera, A
    Mayani, H
    [J]. LEUKEMIA RESEARCH, 2005, 29 (02) : 215 - 224
1234